Zentalis Pharmaceuticals (NASDAQ:ZNTL) Announces Quarterly Earnings Results

Key Points

• Zentalis Pharmaceuticals reported an earnings per share (EPS) of ($0.37), exceeding analysts' expectations of ($0.56) by $0.19.
• The company's stock experienced a 5.1% increase following the earnings release, with current trading around $1.45.
• Analysts have mixed forecasts for Zentalis, with target prices ranging from $4.00 to $10.00, reflecting an average rating of "Moderate Buy."

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.19, Zacks reports.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock traded up $0.02 during trading hours on Tuesday, hitting $1.42. The company had a trading volume of 426,948 shares, compared to its average volume of 1,241,055. The company has a market cap of $102.08 million, a P/E ratio of -0.63 and a beta of 1.71. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $5.44. The company's 50-day moving average is $1.38 and its two-hundred day moving average is $1.55.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZNTL. Wall Street Zen upgraded Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Saturday. Wedbush reaffirmed a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Wells Fargo & Company decreased their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Finally, HC Wainwright raised Zentalis Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 7th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $8.20.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

An institutional investor recently raised its position in Zentalis Pharmaceuticals stock. AQR Capital Management LLC grew its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 177.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 619,330 shares of the company's stock after purchasing an additional 396,233 shares during the period. AQR Capital Management LLC owned about 0.86% of Zentalis Pharmaceuticals worth $985,000 as of its most recent SEC filing.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.